1. Home
  2. LXEO vs JRI Comparison

LXEO vs JRI Comparison

Compare LXEO & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

SELL

Current Price

$3.19

Market Cap

348.7M

Sector

N/A

ML Signal

SELL

Logo Nuveen Real Asset Income and Growth Fund of Beneficial Interest

JRI

Nuveen Real Asset Income and Growth Fund of Beneficial Interest

SELL

Current Price

$11.19

Market Cap

408.7M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
LXEO
JRI
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
348.7M
408.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LXEO
JRI
Price
$3.19
$11.19
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $20.67
N/A
AVG Volume (30 Days)
★ 1.1M
175.1K
Earning Date
11-16-2026
01-01-0001
Dividend Yield
N/A
★ 9.38%
EPS Growth
★ 39.81
N/A
EPS
N/A
★ N/A
Revenue
★ $654,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$10.31
52 Week High
$10.99
$13.92

Technical Indicators

Market Signals
Indicator
LXEO
JRI
Relative Strength Index (RSI) 50.17 47.31
Support Level $2.72 $10.31
Resistance Level $3.56 $13.16
Average True Range (ATR) 0.38 0.19
MACD 0.04 0.01
Stochastic Oscillator 25.62 25.47

Price Performance

Historical Comparison
LXEO
JRI

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest

Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.

Share on Social Networks: